Navigation Links
Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
Date:4/24/2012

ting activities for the first quarter of 2012 was $144 million compared to $151 million for the first quarter of 2011.  Higher use of cash for working capital to support higher sales levels was the primary contributor to the decline in operating cash flow.  Capital expenditures were $32 million in the first quarter of 2012 compared to $18 million in the first quarter of 2011.  Free cash flow of $112 million for the first quarter of 2012, $193 million of short-term debt and the partial use of cash on hand were used to fund $389 million of acquisitions, pay $24 million in dividends and return $25 million to shareholders through share repurchases.  The Company's debt to capital ratio was 24% at March 31, 2012 and 19% at December 31, 2011. 

Share Repurchases: We acquired 0.4 million shares in the first quarter of 2012 at an average share price of $71.86. There were 121 million shares outstanding at March 31, 2012. The Company expects to continue to offset the dilutive impact of issuing share based incentive compensation with future repurchases,  the timing and amount of which will depend upon market conditions and other factors.

Cautionary Statement: This release contains forward-looking statements.  Such statements involve risk and uncertainty, including financial, business environment and projections, and relate to matters that are not historical facts.  Such statements are preceded by, followed by or include the words "believes," "can," "expects," "plans," "anticipates," "should," "enhances," "estimates," "forecasts," "will" or similar expressions.  Additionally, this release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs, including, without limitation, statements with respect to the Company's expectations, goals, beliefs, intentions, outlook, plans and the like regarding future
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. CRF Institute Names Sigma-Aldrich Top Employer Europe 2012
2. Sigma-Aldrich Enhances Asia-Pacific Customer Support With New Distribution and Packaging Capabilities in India
3. Sigma-Aldrich Corporation Will Hold Its Business Review March 29, 2012
4. Sigma-Aldrich (Nasdaq:SIAL) Declares Increased Quarterly Dividend
5. Sigma-Aldrich Completes Acquisition of BioReliance
6. Avista Capital Partners Agrees to Sell BioReliance to Sigma-Aldrich Corporation
7. Sigma-Aldrich Corporation to Present at Upcoming Investor Conference
8. Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81.
9. Sigma-Aldrich Corporation to Present at Upcoming Investor Conferences
10. Sigma-Aldrich (NASDAQ:SIAL) Declares Quarterly Dividend
11. Sigma-Aldrich Opens European Headquarters in St. Gallen, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... DIEGO , June 19, 2013   Nektar Therapeutics ... results from a human abuse liability (HAL) study for ... rate of entry into the brain.  This slow rate of ... to the abuse of and addiction to current opioid analgesics. ... NKTR-181 was rated similar to placebo in "drug liking" ...
(Date:6/19/2013)... -- Today leading web researchers Change Sciences Group ( ... sites for usability, engagement, and conversion. The rankings are ... compares how people experience sites with competitors and with ... top three performers are easier to use, more engaging ... have usability problems, lack aspects of design that compel ...
(Date:6/19/2013)... , June 19, 2013 Today ... solutions, introduced the next-generation of its Employer ... allows health plans to provide their employer groups ... health factors, medical and prescription drug claims, network ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer ...
Breaking Medicine Technology:Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2
... In 2009, more than 30 million people delayed seeking ... needed care due to the rising costs of healthcare in ... and cannot afford their prescriptions, medical treatment or even a ... dietary supplement brand with more than 10 years in the ...
... Jan. 24, 2011 NxStage Medical, Inc. (Nasdaq: ... products, today announced the addition of Nancy J. Ham ... of Jonathan T. Silverstein. Mr. Silverstein, General ... the Company,s 2008 financing, in which OrbiMed was the ...
Cached Medicine Technology:Codeco® Nutrilife Brings Hope to Hispanics Through Alternative Medicine 2NxStage® Appoints Nancy J. Ham to Its Board of Directors and Announces Resignation of Board Member Jonathan T. Silverstein 2
(Date:6/19/2013)... Pa. (June 19, 2013) The results of three ... of Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... study indicates that continuous "machine learning" using artificial neural ... in patients with advanced brain cancers. Another study in ...
(Date:6/19/2013)... is available in Spanish . ... neglected diseases, it goes by the name of the 10/90 ... devoted to conditions that accounted for 90 per cent of ... that the Drugs for Neglected Diseases initiative (DNDi) came into ... organization has been granted the BBVA Foundation Frontiers of Knowledge ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 ... of neurologists, neurosurgeons, psychiatrists and urologists with specialists ... The team works with patients and their family ... overall quality of life. Patients also have the ... trials and research. , “Movement disorders can be ...
(Date:6/19/2013)... June 19, 2013 North Carolina-based ... organizational changes to advance development of its technologies. ... “To support the advanced development of our product ... to the Company’s management structure and engaged industry ... Company announced that Michael Galiger will serve as ...
(Date:6/19/2013)... DiscountFurnaceFilter.com, the number one solution for homeowner’s indoor air ... kit at an exceptional price. The 5-2-1 Compressor Saver (also ... unit during start up, saving wear and tear on the ... out. , The 5-2-1 Compressor Saver works by ... power to start and drastically reduces the rush of heat ...
Breaking Medicine News(10 mins):Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3
... how the risk of death and heart attack can be ... that doubling the usual dose of an anti-clotting drug before ... in which a balloon-tipped catheter is threaded into an artery. ... and unblock the vessel. A small synthetic tube - stent ...
... has been found out that there is no association between ... -- and breast cancer. More than 43,000 women were studied ... had their average daily intake of acrylamide monitored. No evidence ... whose intake was higher was documented. Acrylamide was first discovered ...
... In the 83rd General Session of the International Association ... have presented the results of a study// that says ... bad breath. ,Oral bad odor or so called ... compounds like hydrogen sulfide. The study revealed that volunteers ...
... A new study has found out that depression has to ... anti-depressants // used to treat the same. The study was ... ,At first glance, results showed both the newer and older ... attack within the first month of being prescribed.The older class ...
... drug tezosentan did not improve worsening heart failure or prevent ... hopes. The above fact was found out in the largest ... was conducted to evaluate if something more could be done ... hospital discharge and prevent them from coming back. ,More ...
... help in controlling obesity. A new study coming up in ... that dietary calcium present in the yogurt has got anti-obesity ... and decrease in lipogenesis. ,The study took ... put on balanced deficit diets and the other was put ...
Cached Medicine News:
... versatility, and environmental safety are ... LE-80 K Ultracentrifuge from Beckman ... Optima centrifugation technology, the LE-80 ... effectively provide advanced capability for ...
... With the ability to provide a simple, ... in lipemic samples), the Airfuge CLS delivers ... can be cleaned in 10 minutes, eliminating ... tabletop centrifuge: Reaches top speed in as ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
... Microvolume technology , The ADVIA ... (as low as 2 L/test), reagent consumption ... consumption (25 L/hour) - thus maximizing management ... rapid, 3-second cycle and system throughput of ...
Medicine Products: